Bristol-Myers beats 3rd-qtr forecasts as top drugs deliver

Oct 24 (Reuters) - Bristol-Myers Squibb Co reported better-than-expected third-quarter results, fueled by strong sales of its treatments for blood clots, cancer and arthritis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.